Ardelyx, Inc. (ARDX) Stock Forecast 2026: P10, P50 & P90 — Probabli.AI
Timestamped ARDX stock forecast with 1-year P10, P50, and P90 price estimates, scenario probabilities, definitions, sources, and limitations.
Direct answer: Ardelyx, Inc. is a promising biopharmaceutical company focusing on addressing unmet medical needs, especially in the kidney and gastrointestinal medicine sectors. Recent FDA fast track designations, successful clinical outcomes, and strong analyst support bolster the outlook. Despite some challenges related to cash burn and patents, Ardelyx's innovative pipeline and strategic partnerships make the company poised for significant growth. The overall sentiment is bullish with an emphasis on well-calibrated investment growth potential. The saved 1-year distribution is P10 $4.5, P50 $10, and P90 $17.5.
Last analyzed · Model: gpt-4o
Ardelyx, Inc. Forecast data
| Estimate | 1-year price | Meaning |
|---|
| P10 | $4.5 | Pessimistic plausible scenario |
| P50 | $10 | Median scenario |
| P90 | $17.5 | Optimistic plausible scenario |
What the numbers mean
P10, P50, and P90 are model-generated scenario estimates: roughly a pessimistic plausible outcome, a median outcome, and an optimistic plausible outcome. They are not calibrated confidence intervals.
Supporting analysis
Ardelyx is well-positioned with its recent FDA fast track designation and expanded pipeline. Analyst consensus is overwhelmingly positive, suggesting potential strong performance ahead.
Sources and limitations
Market and company inputs are primarily sourced through Yahoo Finance and public financial-data interfaces. This page reports a saved AI-generated scenario analysis as of the timestamp above; it is not live data, audited probability, financial advice, or a guaranteed return.
Frequently asked questions
When was this ARDX analysis generated?
April 29, 2026.
Is this a guaranteed ARDX prediction?
No. It is a model-generated scenario assessment with material uncertainty.
View the full ARDX stock analysis · ARDX sentiment · Methodology · Accuracy & validation
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.